An analysis of the RE-LY data showed a trend of better relative performance for dabigatran in centers with lower mean patient-time in therapeutic range (TTR), despite the differences in stroke and intracranial bleeding among centers in different TTR quartiles were not statistically significant [4] .
← all excerpts
Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation.
1
—
—